At a glance
ClinicalIndex Comparison RecordPhase 2Active· 38 enrolled
Drug / intervention
Sorafenib Tosylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of BAY 43-9006 for Imatinib- and Sunitinib Resistant Gastrointestinal Stromal Tumor
In Brief
A Phase 2 clinical trial evaluating Sorafenib Tosylate for Gastrointestinal Stromal Tumor. Active but no longer recruiting, targeting 38 participants across 6 sites.
Detailed Summary
This phase II trial is studying how well sorafenib works in treating patients with malignant gastrointestinal stromal tumor that progressed during or after previous treatment with imatinib mesylate and sunitinib malate. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedDec 2005
Primary CompletionFeb 2010
TodayJul 2026
Study CompletionMar 2027
First PostedDec 15, 2005
Enrollment StartSep 14, 2005
Primary CompletionFeb 11, 2010
Study CompletionMar 31, 2027
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 20.5 years ago
Interventions
Sorafenib Tosylatedrug